WINNERSH, UNITED KINGDOM-- Vernalis plc today announces the results from a Phase II proof-of-concept (POC) study of V158866, its fatty acid amide hydrolase (FAAH) inhibitor, which is being ...
Vernalis plc (LSE: VER), a leading development stage pharmaceutical company with a broad pipeline of clinical and early stage programmes, today announced that the company and its partner, Biogen Idec ...
Vernalis is a revenue generating pharmaceutical company with significant expertise in drug development. It has programs in its NCE development pipeline, which are either partnered or available for ...
Vernalis plc, today announces it has achieved a further research milestone in its drug discovery collaboration with H.Lundbeck A/S (Lundbeck). As a result, Vernalis will receive a payment of £0.4m ...
Vernalis plc today announces the appointment of Nomura Code Securities Limited as financial adviser and corporate broker to the Company with immediate effect. Vernalis is a development stage ...
Vernalis Therapeutics Inc., a subsidiary of Vernalis plc (LSE: VER), today announced that Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results